We are live on ! Find out more
NVS icon

Novartis

1,383 hedge funds and large institutions have $16.2B invested in Novartis in 2025 Q2 according to their latest regulatory filings, with 119 funds opening new positions, 494 increasing their positions, 476 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 75

21% more funds holding in top 10

Funds holding in top 10: 1417 (+3)

5% more capital invested

Capital invested by funds: $15.4B → $16.2B (+$811M)

2% more funds holding

Funds holding: 1,3561,383 (+27)

4% more repeat investments, than reductions

Existing positions increased: 494 | Existing positions reduced: 476

0.27% less ownership

Funds ownership: 6.59%6.32% (-0.27%)

19% less call options, than puts

Call options by funds: $269M | Put options by funds: $331M

Holders
1,383
Holders Change
+27
Holders Change %
+1.99%
% of All Funds
18.21%
Holding in Top 10
17
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+21.43%
% of All Funds
0.22%
New
119
Increased
494
Reduced
476
Closed
75
Calls
$269M
Puts
$331M
Net Calls
-$61.7M
Net Calls Change
-$26.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Wealth Enhancement Advisory Services
101
Wealth Enhancement Advisory Services
Minnesota
$17.9M +$651K +5,780 +4%
Cetera Investment Advisers
102
Cetera Investment Advisers
Illinois
$17.8M +$2.34M +20,733 +16%
WIC
103
Wilkins Investment Counsel
Massachusetts
$16.9M -$1.12M -9,895 -7%
CIM
104
Coleford Investment Management
Canada
$16.8M -$84.5K -750 -0.5%
BCAM
105
Boston Common Asset Management
Massachusetts
$16.8M -$1.34M -11,877 -8%
JGUA
106
John G. Ullman & Associates
New York
$16.6M -$80.7K -716 -0.5%
FFIC
107
First Fiduciary Investment Counsel
Ohio
$16.6M +$51.3K +455 +0.3%
PMG
108
ProVise Management Group
Florida
$16.5M +$411K +3,644 +3%
GHA
109
GW Henssler & Associates
Georgia
$16.4M -$114K -1,012 -0.7%
Mercer Global Advisors
110
Mercer Global Advisors
Colorado
$16.3M -$800K -7,101 -5%
ISL
111
Ingalls & Snyder LLC
New York
$16M +$650K +5,769 +5%
VPIM
112
Vanguard Personalized Indexing Management
California
$15.2M +$1.81M +16,063 +15%
TAM
113
Tocqueville Asset Management
New York
$14.1M -$133K -1,179 -1%
Neuberger Berman Group
114
Neuberger Berman Group
New York
$14M +$695K +6,169 +6%
Allspring Global Investments
115
Allspring Global Investments
North Carolina
$13.6M -$265K -2,349 -2%
EIA
116
Edgemoor Investment Advisors
Maryland
$13.4M -$180K -1,595 -1%
P
117
&Partners
Tennessee
$12.9M +$1.08M +9,588 +10%
CAM
118
Cresset Asset Management
Illinois
$12.7M -$1M -8,881 -8%
Pathstone Holdings
119
Pathstone Holdings
New Jersey
$12.5M -$2.98M -26,459 -20%
New York State Common Retirement Fund
120
New York State Common Retirement Fund
New York
$12.4M +$115K +1,020 +1%
RWM
121
Ritholtz Wealth Management
New York
$12.2M +$1.05M +9,355 +10%
Federated Hermes
122
Federated Hermes
Pennsylvania
$12.1M -$166K -1,473 -1%
ZAM
123
Zevin Asset Management
Massachusetts
$12M -$245K -2,173 -2%
EWA
124
Exencial Wealth Advisors
Oklahoma
$11.9M -$2.21M -19,603 -17%
Rockefeller Capital Management
125
Rockefeller Capital Management
New York
$11.8M -$442K -3,920 -4%

NVS Hedge Fund Activity: Q2 2025 in Review

1,383 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2025, worth a combined $16.2B — up 5.3% from $15.4B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new NVS positions and 75 closed out — a net gain of 44 holders — while 494 added to existing stakes and 476 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $56.8M. The largest seller was CIBC World Market, cutting an estimated $192M.

  • 1,383 institutional investors held Novartis (NVS) as of Q2 2025, up from 1,356 in Q1 2025.
  • Funds reported $16.2B of Novartis stock for Q2 2025, up 5.3% quarter-over-quarter.
  • 119 funds opened new Novartis positions in Q2 2025 and 75 closed out, a net change of +44 holders.
  • The largest Novartis buyer in Q2 2025 was Morgan Stanley, an estimated $56.8M added.
  • The largest Novartis seller in Q2 2025 was CIBC World Market, an estimated $192M sold.

Based on aggregated 13F filings for Q2 2025.